1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | Licensing Program Analyst (LPA) Avelina Martinez contacted the facility via telephone to commence a case management call on 04/13/2021 due to COVID-19 and pre-cautionary measures. LPA Martinez identified herself and discussed the purpose of the call and the elements of the allegation with Theresa Pettapiece.
The purpose of the case management visit is to follow up on a learned deficiency during a complaint investigation 27-AS-20210121165503. The following deficiency was discovered:
On 01/02/2021, resident 1's (R1) Lorazepam pill form was discontinued and a new liquid form order was given to the facility which, was Lorazepam Intensol 2 MG/M 30 ML “give 0.25 ML (0.5MG) by mouth every 8 hours routine for anxiety and give 0.25 ML (0.5MG) by mouth every 4 hours as needed for anxiety. Resident 1's (R1) written liquid count sheet has a Lorazepam balance and time discrepancy. The Lorazepam balance entries consist of the following: 01/05/2021 first entry at 1PM states 25 ML; the 01/05/2021 second entry at 12 PM states 20 ML; on 01/06/2021 entry at 12PM states 15 ML; on 01/07/2021 first entry at 12PM states 10 ML; the 01/07/2021 second entry at 3:45 states 0.25. As a result of the medication records review, the facility did not maintain R1’s medication record.
Deficiencies are cited, per Title 22 Regulations, and can be found on 9099-D and appeals right given. An exit interview was conducted with Theresa Pettapiece via telephone, and a copy of this report was provided to Theresa Pettapiece via email, and an electronic email read receipt confirms receiving these documents.
|